New SGLT2 Inhibitors (Kidney & Heart) treatments in trials

Empagliflozin, Dapagliflozin — glycaemic control, heart failure & chronic kidney disease. Track the treatments still in clinical testing and see which are closest to an FDA decision.

69Closest to approval (Phase 3)
65Mid-stage (Phase 2)
56Early stage (Phase 1)
862Total recruiting
In one line

862 sglt2 inhibitors (kidney & heart) trials are recruiting right now, 69 of them in Phase 3 — the stage immediately before an FDA decision.

Recruiting now

Twelve of the currently recruiting studies. Open one for a plain-English summary of who it is for and what it involves.

NCT07675551NARecruitingPeel Family Diabetes Prevention ProgramSponsorTrillium Health PartnersEnrolling280Summary NCT06735599NARecruitingWild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood PressureSponsorGeorgia State UniversityEnrolling40Summary NCT05074732RecruitingDundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.SponsorHealth Service Executive, IrelandEnrolling350Summary NCT06338215NARecruitingAdvice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease and MortalitySponsorClinica Universidad de Navarra, Universidad de NavarraEnrolling10,000Summary NCT05958706RecruitingMitochondrial Substrate Utilization in the Diabetic Human HeartSponsorHeinrich-Heine University, DuesseldorfEnrolling500Summary NCT07778524Phase 1RecruitingAlpelisib Challenge Test (ACT)SponsorColumbia UniversityEnrolling15Summary NCT07106879RecruitingNon-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.SponsorClindove Research LLCEnrolling7,000Summary NCT06115876RecruitingKuwait Adult Diabetes Epidemiological Multidisciplinary (KADEM) ProgramSponsorDasman Diabetes InstituteEnrolling2,000Summary NCT07167004NARecruitingThe GRoceries Aimed at Increasing Nutrition StudySponsorUniversity of PennsylvaniaEnrolling216Summary NCT05933174NARecruitingPromoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 DiabetesSponsorUniversity Hospitals Cleveland Medical CenterEnrolling220Summary NCT05354947NARecruitingUltrasound Effects on Glycemic Control in T2DMSponsorYale UniversityEnrolling30Summary NCT02836808NARecruitingValidation of an Integrated Attention Model for Patients With Type 2 DiabetesSponsorInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranEnrolling1,200Summary

View all 862 on ClinicalTrials.gov

Already approved for this area

SGLT2 Inhibitors

Jardiance, Farxiga, Invokana, Steglatro — approved products with their NDC records and billing codes.

Open the class

Every NDC in this class

The FDA registry filtered to sglt2 inhibitors, with packaging and 11-digit billing conversions.

Search the directory

Loading the trial explorer…